Introduction of biosimilars for the rheumatology drug adalimumab ... could dissuade most prescribers from switching. Another example (and perhaps driver) of that latter success came in June ...

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.

P.C., a seven-office rheumatology practice in Maryland; Washington, DC; and Virginia. Many other biosimilars for rheumatologic medications are launching in the next 2 years, “and we’re very ...